Results 111 to 120 of about 1,112,126 (259)

Full-length and N-terminally truncated recombinant interleukin-38 variants are similarly inefficient in antagonizing interleukin-36 and interleukin-1 receptors

Cell Communication and Signaling
Background Interleukin (IL)-38 is an IL-1 family cytokine that was proposed to exert anti-inflammatory effects. However, its mechanisms of action are not well understood and the identity of the IL-38 receptor(s) remains debated.
Alejandro Diaz-Barreiro, Dominique Talabot-Ayer, Arnaud Huard, Gea Cereghetti, Jenna Tonacini, Mike Maillasson, Antonio Francés-Monerris, Erwan Mortier, Gaby Palmer   +8 more
doaj   +1 more source

Reviews of Interleukin-37: Functions, Receptors, and Roles in Diseases

, 2018
Interleukin-37 (IL-37) is an IL-1 family cytokine discovered in recent years and has 5 different isoforms. As an immunosuppressive factor, IL-37 can suppress excessive immune response.
Jing Liu, Bo Han, Hailin Jia
core   +1 more source

Chronic Effects of Subcutaneous Interleukin-2 Therapy on Soluble Interleukin-2 Receptors in Advanced Small Cell Lung Cancer

The International Journal of Biological Markers, 1993
The increase in IL-2 receptor serum levels is one of the most typical changes in immune parameters during IL-2 cancer immunotherapy. To better define the effects of prolonged IL-2 injection on SIL-2R levels, we evaluated 7 advanced small cell lung cancer
S. Viviani, P.M. Salvini, P. Bidoli, E. Camerini, S. Spinazzé, F. Arienti, L. Rivoltini, V. Motta   +7 more
doaj   +1 more source

Real‐World Safety and Effectiveness of JAK Inhibitors in Systemic Sclerosis: A Propensity‐Matched Study From the EUSTAR Cohort

Arthritis Care &Research, EarlyView.
Objective JAK inhibitors (JAKi) have shown promising effects in early‐phase studies of systemic sclerosis (SSc). We aimed to assess the safety and explore the effectiveness of JAKi compared to conventional immunosuppressants in SSc. Methods A longitudinal retrospective study of the European Scleroderma Trials and Research Group (EUSTAR) cohort was ...
Stefano Di Donato, Marie‐Elise Truchetet, Marco Minerba, Oliver Distler, Juan José Alegre Sancho, Yolanda Braun‐Moscovici, Christina Bergmann, Petros Sfikakis, Jeska K. de Vries‐Bouwstra, Murray Baron, Silvia Bellando‐Randone, Lorenzo Dagna, Christopher P. Denton, Madelon C. Vonk, Vanessa Smith, Ivan Castellvi, Gabriela Riemekasten, Andra Balanescu, Masataka Kuwana, Maria De Santis, Kamal Solanki, Anastas Batalov, Vahan Mukuchyan, Marco Matucci‐Cerinic, Yannick Allanore, Francesco Del Galdo, Michael Hughes, EUSTAR Collaborators   +27 more
wiley   +1 more source

Killer-Cell Inhibitory Receptors, CD158a/b, are Upregulated by Interleukin-2, but not Interferon-γ or Interleukin-4

Mediators of Inflammation, 1999
Although it is now accepted that killer-cell inhibitory receptors (KIRs), which were molecularly cloned in 1995, deliver negative signals to natural killer (NK) cells regarding the recognition of target cells, it is still unclear how the expression of ...
Toshiaki Kogure, Hiroshi Fujinaga, Atsushi Niizawa, Le Xuan Hai, Yutaka Shimada, Hiroshi Ochiai, Katsutoshi Terasawa   +6 more
doaj   +1 more source

Short‐Term Response to Biologic Therapy in Psoriatic Arthritis Is Not Influenced by Disease Duration at Initiation of Therapy

Arthritis Care &Research, EarlyView.
Objective We aimed to determine whether the short‐term response to biologics in biologic‐naive psoriatic arthritis (PsA) is better in patients initiating biologic treatment early in the disease course. Methods Patients with PsA who started on biologic therapy from the year 2000 to 2025 were included for analysis.
Sung Min Cho, Shangyi Gao, Daniel Pereira, Richard J. Cook, Dafna D. Gladman   +4 more
wiley   +1 more source

Effects of interleukin 4 on neonatal B lymphocyte tolerance

, 1989
Perturbation of antigen receptors on mouse neonatal B cells by rabbit anti-mouse IgM antibody was shown to inhibit cell proliferation in response to the B cell mitogen lipopolysaccharide.
Richard L. Riley, James S. Peacock, Valerian B. Pinto, Peacock, James S, Pinto, Valerian B, Riley, Richard L   +5 more
core   +1 more source

Impact of Six‐Month Monitoring Compared to Three‐Month Monitoring of Laboratories During Methotrexate Therapy

Arthritis Care &Research, EarlyView.
Objective To evaluate whether extending the American College of Rheumatology–recommended monitoring interval for complete blood count and liver function tests in patients receiving methotrexate (MTX) affects timely detection of medication‐related toxicity.
Spencer Simko, Ray Zhang, Sohini Mukherjee, Puneet Bajaj, Bonnie L. Bermas   +4 more
wiley   +1 more source

Real‐World Effectiveness and Safety of Secukinumab in Giant Cell Arteritis: An Italian Multicenter Cohort Study

Arthritis Care &Research, EarlyView.
Objective The objective of this study was to evaluate the real‐world effectiveness and safety of secukinumab in patients with giant cell arteritis (GCA). Methods This multicenter retrospective study included patients with GCA who received secukinumab at 14 Italian centers with at least six months of follow‐up.
Luca Iorio, Federica Davanzo, Caterina Ricordi, Milena Bond, Ruggiero Mascolo, Jacopo Mora, Alessandro Tomelleri, Angelo Fassio, Francesca Cuzzocrea, Sara Monti, Edoardo Conticini, Fabiola Atzeni, Paolo Delvino, Carlotta Nannini, Augusta Ortolan, Francesco Pollastri, Ester Vivaldelli, Chiara Marvisi, Paola Toniati, Antonio Brucato, Alessandra Milanesi, Francesca Regola, Enrico Tombetti, Lorenzo Dagna, Roberta Ramonda, Christian Dejaco, Luca Quartuccio, Carlo Salvarani, Roberto Padoan   +28 more
wiley   +1 more source

Molecular Mechanism of NLRP3 Inflammasome in Inflammatory Diseases and Tumors

Immunity, Inflammation and Disease
The nucleotide‐binding and oligomerization domain‐like receptors (NLRs) are pattern recognition receptors. Nucleotide‐binding oligomerization domain‐like receptor family pyrin domain‐containing 3 (NLRP3), a member of the NLRs family, can form a protein ...
Le‐Lan Gong, He‐Jiang Zhou, Quan‐Ming Zhao, Ning Xu, Feng‐Chang Huang, Ling‐Yan Su, Wen‐Liang Li   +6 more
doaj   +1 more source